Investigating Cooperation Between KEAP1 and LKB1 Inactivation in Lung Adenocarcinoma
Abstract
Preliminary analysis in our laboratory reveals concurrent mutation of the LKB1 and KEAP1 tumor suppressors correlate with poor overall survival in lung adenocarcinoma (LA). Phenotypically, there is evidence to suggest that inactivation of KEAP1 may support adaptation to increased oxidative stress that results from LKB1 inactivation. We have found that inactivation of KEAP1 in the background of LKB1 inactivation results in increased growth and resistance to treatment. Further, we have evidence that cross-talk from the PERK kinase, may also further support adaptation to oxidative stress in combination with KEAP1 inactivation in LKB1-deficient LA. These findings suggest that KEAP1/LKB1 inactivation may represent a critical step in LA tumorigenesis and may have a role in therapeutic resistance.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2019
- Accession Number
- AD1087451
Entities
People
- Landon J. Inge
Organizations
- Dignity Health